Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Chief Medical Officer Sarah Gheuens completed a disposition of common stock on July 1, 2026, with total proceeds reaching $150,502. The transaction involved the sale of 4,007 shares at a per-share price of $37.56. This activity was executed to satisfy tax withholding requirements associated with the vesting of restricted stock units. The sale was facilitated under a Rule 10b5-1 trading plan, which was originally established on July 1, 2023.
Following the sale, Ms. Gheuens acquired 8,375 shares of common stock through the vesting of these restricted stock units. The units were granted on July 1, 2023, and are scheduled to vest in three equal annual installments, with the first installment beginning on July 1, 2024. Post-transaction, Ms. Gheuens holds a total of 84,645 shares of Agios Pharmaceuticals common stock. The stock has shown notable recent performance, with shares increasing 36% over the past six months and trading at $37.58. According to InvestingPro analysis, the stock appears undervalued relative to a Fair Value of $44.08, indicating potential upside from current levels.
Agios Pharmaceuticals has also announced significant developments in its pipeline and strategic initiatives. The company presented detailed results from its RISE UP Phase 3 trial of mitapivat, focusing on patients with sickle cell disease. The trial results, shared at the European Hematology Association Congress, revealed that 40.6% of patients in the mitapivat group achieved a significant hemoglobin response, compared to 2.9% in the placebo group. Additionally, Agios entered into an agreement with Oscotec to license cevidoplenib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia, for $25 million upfront and potential milestone payments. Meanwhile, the company decided to halt the development of tebapivat for lower-risk myelodysplastic syndromes after a Phase 2b trial failed to meet its advancement criteria. This decision follows disappointing trial results, marking a setback for the company. In a positive move, H.C. Wainwright raised its price target for Agios to $54, maintaining a Buy rating, following updates to its financial model that include cevidoplenib.
Key Points:
- Agios CMO Sarah Gheuens sold 4,007 shares for $150,502 to cover tax withholding obligations tied to restricted stock unit vesting.
- The company reported positive Phase 3 data for mitapivat in sickle cell disease and licensed cevidoplenib for immune thrombocytopenia, while halting development of tebapivat.
- H.C. Wainwright raised its price target to $54, reflecting optimism in Agios' pipeline and financial outlook.
Risks and Uncertainties:
- The halt in tebapivat development for lower-risk myelodysplastic syndromes following disappointing trial results poses a risk to Agios' pipeline diversification and future revenue streams.
- Regulatory and commercialization risks associated with the newly licensed cevidoplenib and the ongoing development of mitapivat could impact the company's strategic focus and financial performance.